title: Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
abstract: Dopamine receptor antagonists are commonly used to counter the adverse effects of opioids such as hallucinations, delusions and emesis. However, most of these agents themselves have side effects, including extrapyramidal symptoms. Here, we investigated the effect of the dopamine system stabilizer aripiprazole on morphine-induced dopamine-related actions in mice. Morphine-induced hyperlocomotion and reward were significantly suppressed by either the dopamine receptor antagonist prochlorperazine or aripiprazole. Catalepsy was observed with a high dose of prochlorperazine, but not with an even higher dose of aripiprazole. The increased level of dialysate dopamine in the nucleus accumbens stimulated by morphine was significantly decreased by pretreatment with aripiprazole. These results suggest that the co-administration of aripiprazole may be useful for reducing the severity of morphine-induced dopamine-related side effects.
authors.affiliation: Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan. narita@hoshi.ac.jp
authors.forename: Minoru
authors.initials: M
authors.lastname: Narita
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takei
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Shiokawa
authors.forename: Yuri
authors.initials: Y
authors.lastname: Tsurukawa
authors.forename: Yuki
authors.initials: Y
authors.lastname: Matsushima
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakamura
authors.forename: Shigemi
authors.initials: S
authors.lastname: Takagi
authors.forename: Megumi
authors.initials: M
authors.lastname: Asato
authors.forename: Daigo
authors.initials: D
authors.lastname: Ikegami
authors.forename: Michiko
authors.initials: M
authors.lastname: Narita
authors.forename: Taku
authors.initials: T
authors.lastname: Amano
authors.forename: Keiichi
authors.initials: K
authors.lastname: Niikura
authors.forename: Keisuke
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Naoko
authors.initials: N
authors.lastname: Kuzumaki
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects*; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000068180:Aripiprazole; D002375:Catalepsy / Q000139:chemically induced; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006948:Hyperkinesis / Q000139:chemically induced; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009020:Morphine / Q000009:adverse effects*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D011346:Prochlorperazine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D012201:Reward; D012720:Severity of Illness Index
chemical_list: D000701:Analgesics, Opioid; D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D010879:Piperazines; D015363:Quinolones; D009020:Morphine; D000068180:Aripiprazole; D004298:Dopamine; D011346:Prochlorperazine